$LUNG

Rose Geoffrey Beran sold $3K of LUNG

Rose Geoffrey Beran (CHIEF COMMERCIAL OFFICER) sold 1,778 shares of Pulmonx Corp (LUNG) at $1.54 on 2026-06-01.

Original reporting
SEC EDGAR · Rose Geoffrey Beran
Published Jun 3, 2026, 8:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LUNG
Neutral
medium confidence
Mentioned
$LUNG
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LUNGNeutralLow
01

Why it matters

The disclosure can influence short-term sentiment, but it does not introduce new clinical, regulatory, or commercial information for the company.

02

Market read

Insider selling at LUNG is a sentiment datapoint rather than a fundamental catalyst.

03

What to watch

The article does not state total insider exposure changes beyond the post-transaction holdings, nor does it provide context for the sale (e.g., tax/vesting).

Relevance 6/10Novelty 4/10Timing: After-hours SEC Form 4 filed June 3, covering a June 1 sale.

Background

SEC Form 4 reports insider transactions in the issuer’s own shares; this filing details an officer’s open-market sale.

Company-level read

Ticker impact

$LUNGNeutralMedium confidence
Context

Pulmonx’s Chief Commercial Officer sold 1,778 shares in an open-market transaction disclosed on SEC Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan indicated and no accompanying company-specific news.

Market effects

Minimal; single insider sale at one small-cap biotech device company typically does not change sector expectations.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity/taxes and may not reflect bearish fundamentals, especially when not tied to a new negative event.

Key entities

  • Pulmonx Corp

    Subject of the insider transaction disclosure; officer sale reported on SEC Form 4.

  • Rose Geoffrey Beran

    Chief Commercial Officer who sold 1,778 shares at $1.54/share.

Related articles

$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

$LUNGMed

Pulmonx Stock Rises On Narrowed Q2 Losses, Margin Gains

Pulmonx (LUNG) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue fell 5% to $22.8M, while gross profit rose to $17.7M and gross margin increased to 78%. Net loss narrowed to $10.1M ($0.24/share). The company reaffirmed FY2026 revenue guidance of $90M-$92M and gross margin around 76%.

$LUNGMed

Pulmonx Corp (LUNG): Results of Operations and Financial Condition

Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lung2q26earningsrelease072.htm EX-99.1 Document Exhibit 99.1 Pulmonx Reports Second Quarter 2026 Financial Results Redwood City, CA - July 29, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lu